Silver Book Fact

Effects of optimal anticoagulation among AFib patients

If 50% of individuals with atrial fibrillation who do not receive prophylaxis were optimally anti-coagulated, 19,380 emboli would be prevented and $1.1 billion would be saved each year.

Caro J. An Economic Model of Stroke in Atrial Fibrillation: The cost of suboptimal oral anticoagulation. Am J Managed Care. 2004; 10(14): S451-61. https://www.ajmc.com/view/dec04-1992ps451-s461

Reference

Title
An Economic Model of Stroke in Atrial Fibrillation: The cost of suboptimal oral anticoagulation
Publication
Am J Managed Care
Publication Date
2004
Authors
Caro J
Volume & Issue
Volume 10, Issue 14
Pages
S451-61
URL
Read Full Resource

Categories

  • Innovative Medical Research
  • Future Value

Related Facts

  • Adjusted-dose warfarin reduced stroke risk in AFib patients
    Meta-analysis of randomized trials found that adjusted-dose warfarin reduced stroke risk in atrial fibrillation patients by 60%. Antiplatelet agents reduced risk by 20%.  
  • Stroke rates among Afib patients
    In one year, 58,283 of the 1.265 million Medicare beneficiaries with atrial fibrillation that did not receive prophylaxis suffered a stroke. For those who did receive anti-coagulants, 38,468 suffered strokes.  
  • Cost of warfarin therapy for AFib patients
    In patients with nonvalvular atrial fibrillation (AF) and one additional stroke risk factor, warfarin therapy cost $8,000 per quality-adjusted life-year (QALY) saved.  
  • AFib practice guidelines reduce direct health care costs
    The use of practice guidelines in atrial fibrillation (AF) patients significantly decreased hospitalization and resource utilization—with an average decrease in 30-day total direct health care costs of around $1,400 per patient.  
  • Effect of optimal anticoagulation
    If 50% of atrial fibrillation patients who currently receive warfarin in routine medical care were optimally anticoagulated, 9,852 emboli would be prevented and $1.3 billion would be saved each year.